活检类

Search documents
收入3亿!增长14.56%!安杰思最新半年报
思宇MedTech· 2025-08-11 09:08
Core Viewpoint - The company, Anjisi, reported a revenue increase of 14.56% in the first half of 2025, indicating strong growth in both domestic and international markets [3][6]. Financial Data - The total revenue for the first half of 2025 was approximately 302.43 million RMB, compared to 264.00 million RMB in the same period last year, reflecting a growth of 14.56% [3]. - The total profit for the period was 149.13 million RMB, a slight increase of 2.78% from 145.10 million RMB year-on-year [3]. - The net profit attributable to shareholders was 126.02 million RMB, showing a year-on-year increase of 1.26% [3]. - The net profit after deducting non-recurring gains and losses was 111.51 million RMB, which represents a decline of 7.06% compared to the previous year [3][4]. - The net cash flow from operating activities was 75.69 million RMB, down 34.90% from 116.27 million RMB in the same period last year [4]. Market Performance - Domestic market sales revenue was approximately 137 million RMB, reflecting a growth of 10.07% year-on-year [6]. - International market sales revenue reached about 163 million RMB, marking an 18.29% increase compared to the previous year [6]. Research and Development - The company invested 34.46 million RMB in research and development, which is a 33.29% increase year-on-year [4]. - Anjisi has applied for a total of 421 patents, including 270 invention patents, 127 utility model patents, and 24 design patents, with 102 patents granted [6][9]. Company Overview - Anjisi Medical Technology Co., Ltd. specializes in the research, development, production, and sales of minimally invasive diagnostic and therapeutic instruments, established in December 2010 and successfully listed in May 2023 [7]. - The company's product range includes hemostatic closure devices, EMR/ESD devices, biopsy tools, ERCP devices, and various instruments, widely used in five major fields: digestive endoscopy, respiratory endoscopy, ENT endoscopy, urological endoscopy, and gynecological endoscopy [7].
南微医学收盘下跌2.65%,滚动市盈率27.81倍,总市值158.73亿元
Sou Hu Cai Jing· 2025-08-08 11:33
Group 1 - The core viewpoint of the articles highlights the performance and valuation of Nanwei Medical, which has a current stock price of 84.5 yuan and a rolling PE ratio of 27.81 times, significantly lower than the industry average of 55.70 times [1][2] - As of March 31, 2025, Nanwei Medical has 13,313 shareholders, an increase of 639 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] - The company specializes in the research, manufacturing, and sales of minimally invasive medical devices, with key products including biopsy, hemostasis, closure devices, and various imaging systems [1] Group 2 - In the first quarter of 2025, Nanwei Medical reported a revenue of 699 million yuan, representing a year-on-year growth of 12.75%, and a net profit of 161 million yuan, also reflecting a year-on-year increase of 12.18%, with a gross margin of 65.69% [1] - The company ranks 56th in terms of PE ratio within the medical device industry, which has a median PE of 39.08 times [1][2] - The industry average PE ratio is 55.70 times, indicating that Nanwei Medical is undervalued compared to its peers [2]
南微医学收盘上涨5.93%,滚动市盈率29.29倍,总市值167.17亿元
Sou Hu Cai Jing· 2025-08-04 11:53
序号股票简称PE(TTM)PE(静)市净率总市值(元)13南微医学29.2930.224.18167.17亿行业平均 54.3250.504.72116.17亿行业中值38.1137.682.7056.52亿1九安医疗10.9911.120.87185.49亿2新华医疗 15.9814.821.30102.47亿3英科医疗16.0817.331.43254.01亿4山东药玻16.1016.151.85152.30亿5振德医疗 16.4615.511.0559.74亿6奥美医疗16.5616.231.7059.84亿7康德莱17.8617.871.4838.48亿8九强生物 17.9416.682.2088.83亿9维力医疗18.0819.322.2742.38亿10奥泰生物18.1519.131.4757.88亿11鱼跃医疗 19.9219.542.69352.87亿12安图生物20.2719.352.60231.08亿 来源:金融界 南微医学科技股份有限公司的主营业务是微创医疗器械的研发、制造和销售。公司的主要产品是活检 类、止血和闭合类、EMR/ESD类、扩张类、ERCP类、EUS/EBUS类、消融仪、消 ...
南微医学收盘下跌1.27%,滚动市盈率27.68倍,总市值157.94亿元
Sou Hu Cai Jing· 2025-07-29 11:04
最新一期业绩显示,2025年一季报,公司实现营业收入6.99亿元,同比12.75%;净利润1.61亿元,同比 12.18%,销售毛利率65.69%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13南微医学27.6828.553.95157.94亿行业平均 55.4650.344.76115.47亿行业中值37.7437.642.7056.85亿1九安医疗10.9411.070.86184.69亿2英科医疗 13.3414.381.19210.74亿3新华医疗15.3914.261.2598.65亿4振德医疗16.1515.221.0358.62亿5山东药玻 16.2816.331.87154.02亿6奥美医疗16.3015.971.6858.89亿7康德莱17.0517.061.4136.73亿8九强生物 17.6216.382.1687.24亿9奥泰生物18.0719.051.4657.63亿10维力医疗18.5919.332.1842.41亿11三鑫医疗 20.0220.033.2945.55亿12鱼跃医疗20.0519.662.71355.08亿 来源:金融界 截至2025年一季报,共有17 ...
南微医学收盘上涨1.08%,滚动市盈率25.27倍,总市值144.19亿元
Sou Hu Cai Jing· 2025-07-23 12:52
Group 1 - The core viewpoint of the articles highlights the performance and valuation of Nanwei Medical, which has a current PE ratio of 25.27, significantly lower than the industry average of 53.52 [1][2] - As of the first quarter of 2025, Nanwei Medical reported a revenue of 699 million yuan, representing a year-on-year growth of 12.75%, and a net profit of 161 million yuan, also showing a year-on-year increase of 12.18% [1] - The company operates in the minimally invasive medical device sector, with key products including biopsy, hemostasis, closure devices, and various imaging systems [1] Group 2 - The average PE ratio for the medical device industry is 53.52, with a median of 37.14, indicating that Nanwei Medical is undervalued compared to its peers [2] - The total market capitalization of Nanwei Medical is 14.419 billion yuan, with 17 institutions holding a total of 5.4605 million shares valued at 369 million yuan [1][2] - The company's gross profit margin stands at 65.69%, reflecting strong profitability within its operational framework [1]
南微医学收盘上涨3.46%,滚动市盈率23.21倍,总市值132.47亿元
Sou Hu Cai Jing· 2025-07-04 11:36
Company Overview - Nanwei Medical's closing price on July 4 was 70.52 yuan, an increase of 3.46%, with a rolling PE ratio of 23.21, marking a new low in 87 days, and a total market capitalization of 13.247 billion yuan [1] - The company specializes in the research, development, manufacturing, and sales of minimally invasive medical devices, with key products including biopsy, hemostasis, closure, EMR/ESD, dilation, ERCP, EUS/EBUS devices, ablation instruments, disposable imaging systems, and related consumables [1] Financial Performance - For Q1 2025, Nanwei Medical reported revenue of 699 million yuan, a year-on-year increase of 12.75%, and a net profit of 161 million yuan, also up 12.18%, with a gross profit margin of 65.69% [1] Shareholder Information - As of March 31, 2025, the number of shareholders in Nanwei Medical was 13,313, an increase of 639 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Industry Comparison - The average PE ratio for the medical device industry is 51.05, with a median of 36.62, placing Nanwei Medical at the 50th position in the industry ranking [1][2] - The static PE ratio for Nanwei Medical is 23.94, and the price-to-book ratio is 3.32 [2]
南微医学收盘上涨3.09%,滚动市盈率22.92倍,总市值130.82亿元
Sou Hu Cai Jing· 2025-07-01 11:10
Group 1 - The core viewpoint of the articles highlights the performance and valuation of Nanwei Medical, which closed at 69.64 yuan with a PE ratio of 22.92, marking a new low in 60 days and a total market capitalization of 13.082 billion yuan [1][2] - The average PE ratio for the medical device industry is 51.70, with a median of 37.36, positioning Nanwei Medical at the 49th rank within the industry [1][2] - As of the first quarter of 2025, 17 institutions hold shares in Nanwei Medical, including 11 funds, with a total holding of 10.64733 million shares valued at 7.017 billion yuan [1] Group 2 - Nanwei Medical specializes in the research, manufacturing, and sales of minimally invasive medical devices, with key products including biopsy, hemostasis, closure devices, EMR/ESD devices, dilation devices, ERCP devices, EUS/EBUS devices, ablation instruments, and disposable imaging systems [1] - The latest financial results for the first quarter of 2025 show that the company achieved a revenue of 699 million yuan, a year-on-year increase of 12.75%, and a net profit of 161 million yuan, also reflecting a year-on-year increase of 12.18%, with a gross profit margin of 65.69% [1]
南微医学收盘上涨2.18%,滚动市盈率22.03倍,总市值125.73亿元
Sou Hu Cai Jing· 2025-06-26 11:39
Group 1 - The core viewpoint of the articles highlights the performance and valuation of Nanwei Medical, which closed at 66.93 yuan with a PE ratio of 22.03 times, significantly lower than the industry average of 49.45 times [1][2] - As of the first quarter of 2025, 17 institutions held shares in Nanwei Medical, with a total holding of 10,647.33 million shares valued at 7.017 billion yuan [1] - The main business of Nanwei Medical includes the research, manufacturing, and sales of minimally invasive medical devices, with key products such as biopsy, hemostasis, and imaging systems [1] Group 2 - In the latest financial report for the first quarter of 2025, Nanwei Medical reported a revenue of 699 million yuan, representing a year-on-year increase of 12.75%, and a net profit of 161 million yuan, also up by 12.18%, with a gross margin of 65.69% [1] - The company ranks 49th in terms of PE ratio within the medical device industry, which has a median PE of 35.92 times [1][2] - The industry average PE ratio is 49.45 times, indicating that Nanwei Medical is undervalued compared to its peers [2]
南微医学收盘上涨1.84%,滚动市盈率21.49倍,总市值122.63亿元
Sou Hu Cai Jing· 2025-06-24 13:16
Group 1 - The core viewpoint of the articles highlights the performance and valuation of Nanwei Medical, which closed at 65.28 yuan with a PE ratio of 21.49 and a total market capitalization of 12.263 billion yuan [1][2] - The average PE ratio for the medical device industry is 49.12, with a median of 36.07, positioning Nanwei Medical at the 49th rank within the industry [1][2] - As of March 31, 2025, the number of shareholders for Nanwei Medical increased to 13,313, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] Group 2 - Nanwei Medical specializes in the research, manufacturing, and sales of minimally invasive medical devices, with key products including biopsy, hemostasis, closure devices, EMR/ESD devices, dilation devices, ERCP devices, EUS/EBUS devices, ablation instruments, disposable imaging systems, and related consumables [1] - In the latest quarterly report for Q1 2025, the company reported a revenue of 699 million yuan, reflecting a year-on-year growth of 12.75%, and a net profit of 161 million yuan, also showing a year-on-year increase of 12.18%, with a gross margin of 65.69% [1]
南微医学收盘下跌2.30%,滚动市盈率21.63倍,总市值123.45亿元
Sou Hu Cai Jing· 2025-06-16 10:13
Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Nanwei Medical, which has a current stock price of 65.72 yuan and a market capitalization of 12.345 billion yuan, with a rolling PE ratio of 21.63 times [1] - The medical device industry has an average PE ratio of 49.56 times and a median of 36.18 times, placing Nanwei Medical at the 49th position in the industry ranking [1][2] - As of the first quarter of 2025, 17 institutions hold shares in Nanwei Medical, including 11 funds, with a total shareholding of 106.4733 million shares valued at 7.017 billion yuan [1] Group 2 - Nanwei Medical specializes in the research, development, manufacturing, and sales of minimally invasive medical devices, with key products including biopsy, hemostasis, EMR/ESD, dilation, ERCP, EUS/EBUS devices, ablation instruments, disposable imaging systems, and related consumables [1] - The latest financial results for the first quarter of 2025 show that the company achieved an operating income of 699 million yuan, a year-on-year increase of 12.75%, and a net profit of 161 million yuan, also reflecting a year-on-year increase of 12.18%, with a gross profit margin of 65.69% [1]